linjc16/ctgov huggingface dataset:
Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy

Study Overview
=================
Brief Summary
-----------------
Some of the risk factors for bleeding following bronchoscopy is having a malignancy or an immunocompromised state. The etiology of this remains uncertain. The investigators suspect that individuals with malignancy have abnormalities involving certain factors that influence the coagulation pathway. The investigators plan to measure these factors prior to and after bronchoscopy.

Detailed Description
-----------------
This is a prospective observational study looking at some coagulation factors in individuals with lung cancer. We are looking at BAL and plasma. We would like to see if there is a difference in the levels and if this is the reason behind the higher incidence of hemoptysis in patients with lung cancer.

Official Title
-----------------
Utility of Serum and Bronchoalveolar Fluid Urokinase Like Plasminogen Activator Levels in Defining Patients at Higher Risk of Hemoptysis.

Conditions
-----------------
Hemoptysis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient scheduled to undergo bronchoscopy Exclusion Criteria: Patients with evidence of coagulopathy either iatrogenic or the result of disease process - coagulopathy defined as elevated prothrombin time, activated partial thromboplastin time or platelet count less than 100,000 Patients not scheduled to undergo bronchoalveolar lavage (BAL)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lung cancer<br>Comparison between individuals with and without pulmonary malignancy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Volume of blood loss during the procedure |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hemoptysis
mDixon TSE MRI Sequence And Conventional MRI Sequences In Dysimmune Orbitopathies (DDX)

Study Overview
=================
Brief Summary
-----------------
The dysthyroid orbitopathy (DO) is a chronic disease, evolving during 2 to 3 years, with a hypertrophy and a variable degree of inflammation of the eyelid muscles, the oculomotor muscles and the orbital fat. If the diagnosis of OD is primarily clinical and laboratory, MRI is an additional contribution to the clinic, guiding the therapeutic management by detecting inflammatory lesions not found on clinical examination in 1/3 of cases. The three MRI sequences conventionally practiced ((T2, T2-fat-sat, T1) allow muscles signal analysis oculomotor abnormalities as well as the orbital fat. Compared to these sequences, the main advantage sequences DIXON is a faster acquisition. In addition, DIXON type of imaging overcomes most of these artifacts and to obtain a homogeneous fat removal.

Official Title
-----------------
Study Of The Agreement Between The mDixon TSE Sequence And Conventional MRI Sequences In The Evaluation Of Dysimmune Orbitopathies

Conditions
-----------------
Dysthyroid Ophthalmopathies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient aged 18 to 90 years, suffering from thyroid dysfunction proved by clinical and laboratory tests, with a bilateral clinical dysthyroid orbitopathy and undergoing an eye MRI Exclusion Criteria: Absolute or relative contra-indication to MRI or to a contrast agent gadolinium injection (including pregnant or likely to be, breastfeeding women) Patient under guardianship Patient not willing to participate. Lack of affiliation to social security or medical state aid (AME) or universal health coverage (CMU) Motion artifact on the sequences, not corrected by the repeat sequences Metal artifact prohibiting the analysis of the region of interest

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment, by the determination of the Cohen's kappa coefficient, of the concordance between the conventional sequences (T1, T2, T2-fat-sat) and the mDIXON sequence for the diagnosis of inflammatory or non-inflammatory dysthyroid orbitopathy. |  | One hour |
Prevalence of Cachexia in Patients Undergoing Chemotherapy

Study Overview
=================
Brief Summary
-----------------
Cachexia and low nutritional intake are a common phenomena in cancer patients undergoing chemotherapy. The purpose of this study is to assess prevalence of cachexia and low nutritional intake and the impact on quality of life, fatigue and mortality in patients undergoing chemotherapy. Furthermore interactions between these parameters, tumor disease and chemotherapy, respectively.

Official Title
-----------------
Prevalence and Impact of Cachexia in Cancer Patients Undergoing Chemotherapy

Conditions
-----------------
Cancer, Cachexia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing chemotherapy at least in the second cycle. Patients who have signed a written Informed Consent. Exclusion Criteria: Patients with implanted pacemaker or defibrillator.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nutritional intake | Nutritional intake will be assessed by 24h-recall, which will be analysed with regard to macronutritients | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cachexia | Cachexia will be evaluated using the patient-generated Subjective Global Assessment. | 1 day | 
| Quality of life and fatigue | EORTC QLQ C-30 will be used to assess quality of life and additionally cancer-related fatigue will be evaluated using Brief Fatigue Inventory. | 1 day | 
| Mortality | Mortality will be assesses via telephone or consultation of the local death register | 6 months |
Interest of the Cone Beam Scanner of Temporal Bones in the Analysis of Conductive Hearing Loss

Study Overview
=================
Brief Summary
-----------------
Conductive hearing loss is very common and the incidence increases with age. Until now, the scanner was the reference examination in the etiological diagnosis of deafness. When performing a CT scan of temporal bones for the etiological diagnosis of conductive hearing loss, the quality of the image depends on the scanner brand and the acquisition parameters. The investigators wish to show the usefulness of the cone beam in the diagnosis of conductive hearing loss

Official Title
-----------------
Interest of the Cone Beam Scanner of Temporal Bones in the Analysis of Conductive Hearing Loss

Conditions
-----------------
Conductive Hearing Loss

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major subject (≥18 years old) Subject having performed a CT scan or a cone beam for pre- and post-operative conductive hearing loss between January 01, 2018 and December 31, 2020 Subject who has not expressed his opposition, after being informed, to the reuse of his data for the purposes of this research. Exclusion Criteria: Subject who expressed their opposition to participating in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Show retrospectively that the superiority of the cone beam over the scanner in the diagnosis of conductive hearing loss | This superiority is based on the quality of the images allowing the visualization of the different elements of the middle and inner ears: Ossicles, windows, nerves (VII and VIII), cochlea, labyrinth | Files analysed retrospectively from January 01, 2018 to December 31, 2020 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Conductive Hearing Loss, Cone Beam, Cone beam CT, CBCT, Temporal bones
Biological Investigation of Explanted Endobronchial Lung Valves Study

Study Overview
=================
Brief Summary
-----------------
Rationale: COPD is a severe, often progressive and currently incurable lung disease which affects both the upper airways (chronic bronchitis) as well as the lower airways (emphysema). In advanced stages of the disease air-trapping severely reduces the ability to breathe and subsequently the quality of life. A highly effective treatment for restoring lung mechanical functionality of these patients is the introduction of bronchoscopic lung volume reduction (BLVR), e.g. implanting small silicone/nitinol valves (EBV) inside the airways to reduce air-trapping. Although successfully investigated in a selected group of severe COPD patients, the effectiveness of the treatment can sometimes be short-lived due to fibrotic and granulation responses and tissue-material interactions. Objective: The main objective of this study is to study and understand the underlying biological principles of granulation and fibrotic responses limiting the effectiveness and longevity of BELVR treatment with EBVs, this to investigate the mechanism of action of tissue-device interactions.

Official Title
-----------------
Biological Investigation of Explanted Endobronchial Lung Valves Study - Investigation of the Mechanism of Action of Tissue-device Interactions

Conditions
-----------------
Emphysema or COPD

Intervention / Treatment
-----------------
* Diagnostic Test: tissue and blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elidgible for EBV treatment Exclusion Criteria: Anticoagulation which cannot be stopped prior to the procedure
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| baseline assessment group<br>n=150 patiënts for baseline assessment | Diagnostic Test: tissue and blood sampling<br>* only diagnostics will be peformed<br>|
| clinical need for reintervention group<br>n=20-30 patiënts for re-bronchoscopy | Diagnostic Test: tissue and blood sampling<br>* only diagnostics will be peformed<br>|
| clinical stable controls<br>n=20 stable treated control patiënts | Diagnostic Test: tissue and blood sampling<br>* only diagnostics will be peformed<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the % of the 150 patients that will develop a need for rebronchoscopy after 18 months | frequency | 18 months |
An Evaluation of the Daytime Use of an Investigational Lubricant Eye Drop

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to describe the subjective assessments of an investigational lubricant eye drop.

Official Title
-----------------
An Evaluation of the Daytime Use of an Investigational Lubricant Eye Drop

Conditions
-----------------
Dry Eye

Intervention / Treatment
-----------------
* Other: FID 115958D (Lubricant Eye Drop)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Documented diagnosis of dry eye Current use of Refresh Liquigel, GenTeal Gel Drops or Refresh Celluvisc at least twice daily Exclusion Criteria: Must not have worn contact lenses within 7 days preceding enrollment Must not have had punctal plugs inserted within 30 days preceding enrollment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: FID 115958D<br>Lubricant eye drop | Other: FID 115958D (Lubricant Eye Drop)<br>* 1 drop in each eye at least twice daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Daytime Use Assessment: I would use this product at bedtime for my dry eye symptoms Likert scale (i.e. strongly disagree, disagree, neither disagree nor agree, agree, strongly agree) |  | Day 7 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dry eye, artificial tears
Selective Digestive Decontamination in Carriers of Carbapenem-resistant Klebsiella Pneumoniae

Study Overview
=================
Brief Summary
-----------------
There is an urgent need to control our current national outbreak of carbapenem-resistant Klebsiella pneumoniae (CRKP). The purpose of this study is to eradicate CRKP gastrointestinal carriage using selective digestive decontamination (SDD); with buccal and oral gentamicin and polymyxin E administration. This will reduce infections and hopefully mortality caused by CRKP.

Official Title
-----------------
A Randomized,Double-Blind,Placebo-Controled Trial of Selective Digestive Decontamination Using Oral Gentamicin and Oral Polymyxin E for Eradication of Carbapenem-Resistant Klebsiella Pneumoniae Carriage

Conditions
-----------------
Carriage of Carbapemen-resistant Klebsialle Pneumoniae

Intervention / Treatment
-----------------
* Drug: Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized men and women with a positive rectal swab for CRKP Age 18 years or older Exclusion Criteria: Age less than 18 years Pregnant women, lactating women A known allergy to the study drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 2<br>Oral solution of 0.45% saline and oral solution of H2O & saccharine. Oral gel composed of mineral oil, gelatine powder, pectin, sodium carboxymethylcellulose, polyethylene | Drug: Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.<br>* Arm #1: Oral gentamicin & polymyxin E, gentamicin & polymyxin E buccal gel. Arm #2: Oral placebo solutions, placebo buccal gel.<br>|
| Active Comparator: 1<br>Oral solution and buccal gel of gentamicin and polymyxin E | Drug: Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.<br>* Arm #1: Oral gentamicin & polymyxin E, gentamicin & polymyxin E buccal gel. Arm #2: Oral placebo solutions, placebo buccal gel.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Eradication of CRKP carriage measured by negative rectal swabs |  | Two days after treatment ends | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| No new in-hospital acquisition of CRKP |  | Six weeks |
Physical Evaluation and Quality of Life in the Practice of Fencing in Breast Cancer Support

Study Overview
=================
Brief Summary
-----------------
The data collection of physical evaluations after regular practice of the fencing at patients having surgically been treated for breast cancer highlighted encouraging results both on the functional drawing, and on the improvement of the quality of life.

Detailed Description
-----------------
Recent scientific works show that a regular physical activity decreases the rate of second offense of breast cancer from 20 to 50 % at the women beforehand treated for breast cancer. The objectives: participate as a supplement to the physiotherapist in the mobilization of the operated shoulder act in association with the surgical and medical team to release the adhesions superficial welcome these women hurt through a participative sports project get them a fencing adapted in a friendly atmosphere offer them personalized exchanges to propose a consequent energy expenditure but according to each and to the context have a practice of the operated side make them practise a sport with pleasure and without fatal effects By the practice of the sports activity, investigators wish to help these people upset in their life to find the joy of life, to have projects, to find some pleasure to share moments of user-friendliness. Having led a fight against the disease to help them to lead a new fight of fencer happy to have a practice.

Official Title
-----------------
Practice of Fencing in Breast Cancer Care

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Procedure: fencing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients operated for the breast cancer in the Hospital Rene Dubos patients who have sign a consent patients having supplied an aptitude certificate in fencing Exclusion Criteria: patients who have a contraindication in the sport

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| fencing and patients with breast cancer<br>patients operated for breast cancer followed at the Hospital Rene Dubos | Procedure: fencing<br>* No intervention: practice fencing<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| quality of life questionnary |  | 20 sporting session, an average of one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fencing, cancer
Intrauterine Hyaluronic Acid Gel for Prevention of Intrauterine Adhesions

Study Overview
=================
Brief Summary
-----------------
Women undergoing operative hysteroscopy for removal of retained placenta after delivery will be randomized into two groups. study group - immediately after operative hysteroscopy 5 ml hyaluronic acid gel will be injected into uterine cavity control group - no injection 4-8 weeks after operative hysteroscopy, participants will undergo diagnostic hysteroscopy with no anesthesia , as a part of routine evaluation after removal of retained placenta in Israel. during diagnostic hysteroscopy the uterine cavity will be evaluated and the presence of adhesions and severity of adhesions will be recorded.

Official Title
-----------------
Reduction of Intrauterine Adhesions by Intrauterine Hyaluronic Acid Gel After Hysteroscopic Removal of Retained Products of Conception: Multicenter Prospective Randomized Trial

Conditions
-----------------
Prevenetion of Intrauterine Adhesions by Hyaluronic Acid Gel

Intervention / Treatment
-----------------
* Drug: Intrauterine injection of hyaluronic acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women undergoing hysteroscopic removal of retained placenta after delivery Exclusion Criteria: Known adverse reaction or allergy to hyaluronic acid History of intrauterine adhesions Acute pelvic inflammatory disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: study group<br>study group women in this group will receive intrauterine hyaluronic acid injection after operative hysteroscopy | Drug: Intrauterine injection of hyaluronic acid<br>* operative hysteroscopy - as a part of treatment in cases with retained placenta after delivery diagnostic hysteroscopy - as a routine evaluation after removal of placenta<br>* Other names: diagnostic hysteroscopy;|
| No Intervention: control group<br>women will not receive hyaluronic acid after operative hysteroscopy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| any adhesions | presence of any adhesions in uterine cavity during diagnostic hysteroscopy | 4-8 weeks after intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adhesion scorring | American Fertility Society score for intrauterine adhesions | 4-8 weeks after intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
retained placenta, operative hysteroscopy, intrauterine adhesions, hyaluronic acid